Laman Utama532523 • BOM
add
Biocon Ltd
Tutup sebelumnya
₹330.00
Julat hari
₹317.90 - ₹335.95
Julat tahun
₹270.00 - ₹404.60
Permodalan pasaran
390.93B INR
Bilangan Purata
117.99K
Nisbah P/E
38.58
Hasil dividen
0.15%
Pertukaran utama
NSE
Dalam berita
BIOCON
1.09%
4.23%
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(INR) | Mac 2025info | Perubahan T/T |
---|---|---|
Hasil | 44.54B | 13.70% |
Perbelanjaan pengendalian | 23.02B | 71.69% |
Pendapatan bersih | 3.44B | 154.24% |
Margin untung bersih | 7.73 | 123.41% |
Pendapatan bagi setiap syer | 2.71 | 129.37% |
EBITDA | 11.01B | 16.71% |
Kadar cukai berkesan | 5.63% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(INR) | Mac 2025info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 45.68B | 77.45% |
Jumlah aset | 587.97B | 4.86% |
Jumlah liabiliti | 310.85B | 0.94% |
Jumlah ekuiti | 277.12B | — |
Syer tertunggak | 1.20B | — |
Harga kepada buku | 1.82 | — |
Pulangan pada aset | — | — |
Pulangan pada modal | 3.79% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(INR) | Mac 2025info | Perubahan T/T |
---|---|---|
Pendapatan bersih | 3.44B | 154.24% |
Tunai daripada operasi | — | — |
Tunai daripada pelaburan | — | — |
Tunai daripada pembiayaan | — | — |
Perubahan bersih dalam tunai | — | — |
Aliran tunai bebas | — | — |
Perihal
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Diasaskan
1978
Ibu pejabat
Tapak web
Pekerja
16,315